HighCape Partners

About The Fund

HighCape Partners is a growth equity fund based in New York, that primarily focuses on the life sciences industry. They invest in a variety of sectors, including Connected Health, Medical Device/Tool, and Biotechnology, with a notable emphasis on Oncology. HighCape Partners was founded in 2013 by a group of seasoned executives with a mission to support innovative life sciences companies as they evolve from early stages into flourishing enterprises. Their team consists of industry veterans who leverage their combined experience in founding, financing, leading, growing, and exiting various life sciences companies across multiple segments to add significant value to their investments. HighCape Partners work collaboratively with management teams, providing timely experience and insights to enhance commercial and operational strategies. They take a hands-on approach to partner with companies, augmenting talent and supporting entrepreneurial vision and opportunities to create value for stakeholders and the healthcare system. The team at HighCape brings at least 25 years of experience in all aspects of the global life sciences industry and aims to leverage this depth of experience for the success of their portfolio companies. Their current public portfolio includes companies like Elutia, Quantum-Si, and Wellinks, while their private investments include Cybrexa and Alphina. Noteworthy exits include Cheetah Medical, acquired by Baxter International, and Modifi Biosciences, acquired by Merck in 2024. HighCape Partners also focuses on innovative approaches such as their portfolio company Cybrexa's antigen-independent targeting of tumors and uses proprietary technologies like drug-eluting biomaterial platforms to fuel future medical advances.